

Technical Analysis

Analyst(s)

Greater China Research Team
research-hk@uobkh.com

Tham Mun Hon, CFA

munhon.tham@uobkh.com
+852 2236 6799



Innovent Biologics (1801 HK)

Last price:	HK\$96.15
Support levels:	HK\$93.10/HK\$91.75
Resistance levels:	HK\$105.60/HK\$112.70

Price successfully defended its resistance-turned-support zone, confirming a successful structural polarity flip. The ability to hold above this newly converted structural anchor points to the potential formation of a higher low, keeping the bullish sequence intact. The RSI is turning upward toward its neutral 50-midline. As long as price maintains integrity above this support anchor, we could see a sustained rebound toward higher expansion targets.

Average timeframe: Around two weeks.



Hansoh Pharmaceutical (3692 HK)

Last price:	HK\$34.34
Support levels:	HK\$32.28/HK\$30.76
Resistance levels:	HK\$37.16/HK\$40.12

Price successfully maintained above its gap support zone, re-establishing the gap floor as a primary demand anchor. The RSI has turned bullish and is sloping upward, signalling accelerating trend velocity and renewed buyer control. As long as price holds above this gap support, path-of-least-resistance dynamics favour a sustained upward movement towards higher expansion targets.

Average timeframe: Around two weeks.

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."